{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T10:25:14Z","timestamp":1768559114376,"version":"3.49.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.critrevonc.2015.10.002","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T13:47:01Z","timestamp":1445262421000},"page":"29-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Cancer specific risk in multiple sclerosis patients"],"prefix":"10.1016","volume":"98","author":[{"given":"Athanasios P.","family":"Kyritsis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas","family":"Pavlidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2015.10.002_bib0005","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10549-004-2229-4","article-title":"Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments","volume":"89","author":"Achiron","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0010","first-page":"15","article-title":"Allergy, family history of autoimmune diseases, and the risk of multiple sclerosis","volume":"117","author":"Alonso","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0015","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.21117","article-title":"Environmental risk factors for multiple sclerosis. Part I: the role of infection","volume":"61","author":"Ascherio","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0020","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/01.wnl.0000345366.10455.62","article-title":"Cancer risk among patients with multiple sclerosis and their parents","volume":"72","author":"Bahmanyar","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0025","first-page":"313","article-title":"Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data","volume":"8","author":"Bloomgren","year":"2012","journal-title":"Ther. Clin. Risk Manage."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000356498","article-title":"Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies","volume":"83","author":"Catala-Lopez","year":"2014","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0035","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/01.wnl.0000294325.63006.f8","article-title":"Integrating risk factors: Hla-drb1*1501 and epstein-barr virus in multiple sclerosis","volume":"70","author":"De Jager","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0040","first-page":"235","article-title":"\u201cTumor-mimicking\u201d multiple sclerosis","volume":"22","author":"Di Patre","year":"2003","journal-title":"Clin. Neuropathol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0045","doi-asserted-by":"crossref","first-page":"8226","DOI":"10.1158\/1078-0432.CCR-05-2035","article-title":"The therapeutic implications of intratumoral regulatory t cells","volume":"11","author":"Dranoff","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0050","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1001\/archdermatol.2011.231","article-title":"Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort","volume":"147","author":"Eide","year":"2015","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0055","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/jnnp.2009.175463","article-title":"Cancer in patients with motor neuron disease, multiple sclerosis and parkinson's disease: record linkage studies","volume":"81","author":"Fois","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0060","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/oem.57.6.418","article-title":"Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates","volume":"57","author":"Freedman","year":"2000","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ejca.2008.10.003","article-title":"Vitamin D and skin cancer: a meta-analysis","volume":"45","author":"Gandini","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0070","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/BF00588163","article-title":"Multiple sclerosis masquerading as a mass lesion","volume":"34","author":"Giang","year":"1992","journal-title":"Neuroradiology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.psy.0000116720.09854.a9","article-title":"Relationship between multiple sclerosis exacerbations and stress","volume":"66","author":"Goodin","year":"2004","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0080","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/eji.200526065","article-title":"Reduced suppressive effect of cd4+cd25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis","volume":"35","author":"Haas","year":"2005","journal-title":"Eur. J. Immunol"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0085","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/qjmed\/hcq071","article-title":"Multiple sclerosis and lung cancer: an unexpected inverse association","volume":"103","author":"Handel","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0090","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","article-title":"Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial","volume":"360","author":"Hartung","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0095","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/1352458506073501","article-title":"Smoking is a risk factor for multiple sclerosis: a metanalysis","volume":"13","author":"Hawkes","year":"2007","journal-title":"Mult. Scler."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0100","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/aje\/154.1.69","article-title":"Cigarette smoking and incidence of multiple sclerosis","volume":"154","author":"Hernan","year":"2001","journal-title":"Am. J. Epidemiol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0105","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/jnnp.2008.144667","article-title":"Increasing prevalence and incidence of multiple sclerosis in south east wales","volume":"80","author":"Hirst","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0110","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis Champs study group","volume":"343","author":"Jacobs","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0115","first-page":"S16","article-title":"Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled tria. 1995","volume":"57","author":"Johnson","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0120","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00023210-200721060-00005","article-title":"Oral disease-modifying treatments for multiple sclerosis: the story so far","volume":"21","author":"Kieseier","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0125","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1093\/brain\/aws148","article-title":"Cancer risk in multiple sclerosis: findings from British Columbia, Canada","volume":"135","author":"Kingwell","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/135245859900500418","article-title":"The danish multiple sclerosis registry: a 50-year follow-up","volume":"5","author":"Koch-Henriksen","year":"1999","journal-title":"Mult. Scler."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0135","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1002\/cncr.25524","article-title":"Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million us male veterans","volume":"117","author":"Landgren","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s10072-003-0148-5","article-title":"Multiple sclerosis and exposure to organic solvents, investigated by genetic polymorphisms of the gstm1 and cyp2d6 enzyme systems","volume":"24","author":"Landtblom","year":"2003","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/1352458507083625","article-title":"Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis","volume":"14","author":"Lebrun","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0150","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s00415-011-5929-9","article-title":"Cancer and multiple sclerosis in the era of disease-modifying treatments","volume":"258","author":"Lebrun","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000054782","article-title":"Multiple sclerosis and ultraviolet radiation: time to shed more light","volume":"20","author":"McMichael","year":"2001","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0160","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1600-0404.1996.tb00019.x","article-title":"Multiple sclerosis and cancer in norway: a retrospective cohort study","volume":"93","author":"Midgard","year":"1996","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1600-0404.1991.tb04941.x","article-title":"Cancer incidence following hospitalization for multiple sclerosis in Denmark","volume":"84","author":"Moller","year":"1991","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0170","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0404.1998.tb00632.x","article-title":"The significance of epstein-barr virus seropositivity in multiple sclerosis patients","volume":"97","author":"Munch","year":"1998","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0175","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/ijc.21437","article-title":"Cancer risk among patients with multiple sclerosis: a population-based register study","volume":"118","author":"Nielsen","year":"2006","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04657.x","article-title":"Suppression, subversion and escape: the role of regulatory T cells in cancer progression","volume":"171","author":"Oleinika","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0185","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S1474-4422(06)70581-6","article-title":"Sex ratio of multiple sclerosis in canada: A longitudinal study","volume":"5","author":"Orton","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0190","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/00001648-200211000-00018","article-title":"Organic solvents and the risk of multiple sclerosis","volume":"13","author":"Riise","year":"2002","journal-title":"Epidemiology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0195","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1093\/brain\/awl179","article-title":"Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients","volume":"129","author":"Rinaldi","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0200","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1352458511403642","article-title":"The risk of malignancy is not increased in patients with multiple sclerosis treated with subcutaneous interferon beta-la: analysis of data from clinical trial and post-marketing surveillance settings","volume":"17","author":"Sandberg-Wollheim","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0205","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"6","author":"Schrempf","year":"2007","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0210","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev.immunol.18.1.423","article-title":"Regulatory t cells in autoimmmunity*","volume":"18","author":"Shevach","year":"2000","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2009.09.012","article-title":"Multiple sclerosis, osteoporosis, and vitamin D","volume":"287","author":"Sioka","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0220","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"Stuve","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0225","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00003495-200868010-00005","article-title":"Pharmacological treatment of early multiple sclerosis","volume":"68","author":"Stuve","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0230","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000079947","article-title":"Cancer incidence in multiple sclerosis: a 35-year follow-up","volume":"23","author":"Sumelahti","year":"2004","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0235","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awh219","article-title":"The regulatory role of natural killer cells in multiple sclerosis","volume":"127","author":"Takahashi","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0240","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1200\/JCO.2011.34.5967","article-title":"Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer post hoc analyses of the women's health initiative randomized controlled trial","volume":"29","author":"Tang","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000054783","article-title":"Regional variation in multiple sclerosis prevalence in australia and its association with ambient ultraviolet radiation","volume":"20","author":"van der Mei","year":"2001","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0250","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.10788","article-title":"Multiple sclerosis in us veterans of the vietnam era and later military service: race, sex, and geography","volume":"55","author":"Wallin","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0255","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2165\/00063030-200216030-00003","article-title":"Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials","volume":"16","author":"Wiendl","year":"2002","journal-title":"BioDrugs"},{"key":"10.1016\/j.critrevonc.2015.10.002_bib0260","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s10072-003-0147-6","article-title":"Risk factors of multiple sclerosis: a case-control study","volume":"24","author":"Zorzon","year":"2003","journal-title":"Neurol. Sci."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815300512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T16:56:46Z","timestamp":1537289806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815300512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":52,"alternative-id":["S1040842815300512"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer specific risk in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}